ANIX
Anixa Biosciences Inc (ANIX
NASDAQ · Healthcare · Biotechnology · US
$3.14
+2.78%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.07
From 52W high−39.85%
Volume56311.00
Market cap$109.16M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.07
From 52W high
−39.85%
Volume
56311.00
Market cap
$109.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.9x
P/E (TTM)
—
RSI (14)
53.9
MomentumView details →
1D Return
+2.78%
YTD Return
−1.76%
SummaryUpdated Jul 1, 2026
Anixa Biosciences, Inc. (NASDAQ:ANIX) is a biotechnology company founded in 1982 and originally incorporated as ITUS Corporation before changing its name in October 2018. Based in San Jose, California, the company has transitioned from its original business focus to become a clinical-stage biotechnology firm developing innovative therapies and vaccines for oncology and infectious diseases. The company went public in 1983 and has since evolved into a research-focused organization targeting critical unmet medical needs through advanced immunotherapy and vaccine technologies.
Similar companies
Latest newsMore news →
Anixa Biosciences announced completion of dosing in the fifth cohort of its Phase 1 FSHR-targeted CAR-T trial for recurrent ovarian cancer, with patients receiving 1×10⁷ CAR-positive cells/kg after lymphodepletion.9d agoAnixa Biosciences is developing a breast cancer vaccine, currently about one-third of the way through human testing, designed to prevent recurrence and potentially the disease itself.36d agoAnixa Biosciences received an Australian patent for its breast cancer vaccine.44d ago